Form 4: BioCardia CEO Peter Altman Increases Stake in Company

BioCardia, Inc. President and CEO Peter Altman acquired 5,000 shares of common stock at a price of $0.85 per share.

Summary

• Peter Altman, President and CEO of BioCardia, Inc., purchased 5,000 shares of common stock.
• The transaction occurred on June 9, 2026, at a price of $0.85 per share.
• Following this transaction, Mr. Altman's total beneficial ownership in the company increased to 298,266 shares.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive signal, as it reflects direct financial commitment from the CEO to the company's future.

Positives

• Insider confidence is demonstrated by the CEO's decision to increase his personal equity stake in the company.
• The purchase was made at market price, signaling alignment between management and shareholder interests.

Negatives

• None identified in this filing.

Risks

• The company is subject to the inherent risks of the biotechnology sector, including clinical trial outcomes and regulatory approval processes.

Future Outlook

No specific forward-looking guidance was provided in this Form 4 filing.

Industry Context

StockSavvy.ai notes that insider buying is generally viewed as a positive signal by the market, suggesting that leadership believes the current share price may be undervalued relative to the company's long-term prospects.

Comparison to Industry Standards

• Insider purchases by CEOs are standard practice in the biotech industry to signal confidence during development phases.
• The transaction size is relatively small, which is common for routine insider accumulation.

Stakeholder Impact

• Shareholders may interpret this purchase as a sign of management's confidence in the company's strategic direction.

Next Steps

• No future actions or milestones were disclosed in this filing.

Key Dates

Keywords

BioCardia, BCDA, Insider Trading, Biotechnology, SEC Form 4